Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors. - Wikidata - wikimedia - TriplyDB

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

http://www.wikidata.org/entity/Q35535953

about

Pharmacodynamic Biomarker Development for PI3K Pathway Therapeutics Targeting the PI3K/Akt signaling pathway in gastric carcinoma: A reality for personalized medicine?Molecular predictive markers in tumors of the gastrointestinal tract Phase I combination of pazopanib and everolimus in PIK3CA mutation positive/PTEN loss patients with advanced solid tumors refractory to standard therapy.Phase I dose-escalation study of the mTOR inhibitor sirolimus and the HDAC inhibitor vorinostat in patients with advanced malignancy.Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigms Antiangiogenesis and gene aberration-related therapy may improve overall survival in patients with concurrent KRAS and TP53 hotspot mutant cancer Single cell mutational analysis of PIK3CA in circulating tumor cells and metastases in breast cancer reveals heterogeneity, discordance, and mutation persistence in cultured disseminated tumor cells from bone marrow.Synergistic interactions with PI3K inhibition that induce apoptosis.Pilot study of sirolimus in patients with PIK3CA mutant/amplified refractory solid cancer.PIK3CA gene mutations and overexpression: implications for prognostic biomarker and therapeutic target in Chinese esophageal squamous cell carcinoma.Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials.First-in-human study of CH5132799, an oral class I PI3K inhibitor, studying toxicity, pharmacokinetics, and pharmacodynamics, in patients with metastatic cancer Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience.The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer.Successful control of heavily pretreated metastatic gastric cancer with the mTOR inhibitor everolimus (RAD001) in a patient with PIK3CA mutation and pS6 overexpression Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.Actionable mutations in plasma cell-free DNA in patients with advanced cancers referred for experimental targeted therapies.Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.Personalized medicine for patients with advanced cancer in the phase I program at MD Anderson: validation and landmark analyses.Pilot Study of a Next-Generation Sequencing-Based Targeted Anticancer Therapy in Refractory Solid Tumors at a Korean Institution Presence of both alterations in FGFR/FGF and PI3K/AKT/mTOR confer improved outcomes for patients with metastatic breast cancer treated with PI3K/AKT/mTOR inhibitors Squamousness: Next-generation sequencing reveals shared molecular features across squamous tumor types Next generation sequencing demonstrates association between tumor suppressor gene aberrations and poor outcome in patients with cancer Cyclin-dependent kinase pathway aberrations in diverse malignancies: clinical and molecular characteristics.Concordance between PIK3CA mutations in endoscopic biopsy and surgically resected specimens of esophageal squamous cell carcinoma.Somatic copy number alterations detected by ultra-deep targeted sequencing predict prognosis in oral cavity squamous cell carcinoma.Prospective phase II trial of everolimus in PIK3CA amplification/mutation and/or PTEN loss patients with advanced solid tumors refractory to standard therapy.BRAF mutation testing with a rapid, fully integrated molecular diagnostics system In silico pathway analysis in cervical carcinoma reveals potential new targets for treatment.Genomics of gallbladder cancer: the case for biomarker-driven clinical trial design.Challenges in initiating and conducting personalized cancer therapy trials: perspectives from WINTHER, a Worldwide Innovative Network (WIN) Consortium trial.The Conundrum of Genetic "Drivers" in Benign Conditions.Advanced malignancies treated with a combination of the VEGF inhibitor bevacizumab, anti-EGFR antibody cetuximab, and the mTOR inhibitor temsirolimus.Molecular profiling of head and neck squamous cell carcinoma.Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory Cancers.

P2860

Q26766292-5EE8F89F-A12A-42DF-B75C-E49731E00881 Q26775940-932872D2-9253-4172-A949-97706A0E512E Q28070583-ABD5CB9F-94D9-4BDC-B20A-810EC10FA3A2 Q33422258-F1673D65-B7C5-42F4-8B83-F2691C55E688 Q33435113-5F461019-DC40-4660-87A1-0BF215C34966 Q33591658-976035E4-2CA6-4C08-8735-DC8E6CF8511F Q33756991-F4470812-7782-4F35-861F-784DBBAA2139 Q33779691-FAFBA059-423D-4900-9375-08814759E954 Q33806957-B45547C4-C141-4184-B763-574C3D68C72A Q33822197-3836D79B-E06E-4F86-900B-077850D41FD6 Q33858387-6B9172D5-9142-4FCC-BF8A-A0601BB43DC3 Q33940350-FB021435-BA40-49A8-A08C-A28CD4E62721 Q34471821-527C8CCA-44EC-4BB1-97C3-91F846B99777 Q34532980-51DAFC84-015E-4F62-8DCE-756470FBA153 Q34619163-27FF31A0-9966-4745-9550-02E06AB04751 Q34626967-99860DF9-192A-4E71-B691-349FC4F74E54 Q34957243-30038E04-F005-4187-9D9F-69D436987D5F Q34995919-E6189BD8-266F-4175-8FB3-21E051E81BEA Q35606679-D83460BB-0ADF-44C0-8C89-D886CCF79F03 Q35801713-19B4900E-1317-4645-B9C7-4F3FEAA87D6D Q35828697-00E2C65A-BAB5-44A0-A9B3-4C3B8CCAC2C2 Q35849919-FAE281B9-F633-477F-B06D-EF3D1D11C62F Q35885555-1ED35F60-FA87-452A-85F7-AA2EE182105A Q35899928-AD2517B2-FB7D-4E4E-A5DB-D1699A1CEAE3 Q35997083-2F5EBF61-616A-42B9-ABE5-64A1C1F76BB7 Q36094586-4E20F79E-A854-4EBD-ACC0-8B604F35FFEF Q36184728-7436A4DA-6237-4CA3-BC24-84645BC056C5 Q36188758-B0983413-C516-4A5F-80B5-071D0FEDCF4B Q36188947-AFBBC27E-3292-459B-B14A-FE2DDBF7DF3B Q36244592-54A96883-48D4-437A-9326-6DE68D1B11A5 Q36260672-E325B503-D757-4ECD-9A6C-12CDC7AEA4F7 Q36318871-A7BE909D-C5D8-4DF2-B4D0-9BAFFE4C422C Q36413639-93719BF4-8533-415D-81FF-BDD57A5050DF Q36771946-E54D2F49-9E47-4E7F-8C31-67D3340EB9CA Q37017110-FBC858F4-1484-4AD9-882A-9FE98BCCA0FC Q37220383-8A12BC03-CFF9-47B3-8AE8-3A779018F86F Q37245787-04D5CF02-9A8A-4D23-96C4-EFB091689488 Q37268981-5151489F-C614-457C-881D-E4D0844CA96E Q37337359-2ACED103-2631-4A4E-9E6D-4E7C82A23FFC Q37536016-C1365F9E-AB05-43F1-9496-3E75CB08E590

P2860

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

http://www.wikidata.org/entity/Q35535953

description

2014 nî lūn-bûn

@nan

2014 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

@ast

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

@en

type

label

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

@ast

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

@en

prefLabel

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

@ast

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

@en

P1433

Q35535953-BEA4E423-5289-4A89-9677-79952DCEA3F7

P1476

Q35535953-106DE020-2576-4E17-8422-154C330FDB0B

P2093

Q35535953-0BCBF0F5-CCAE-4918-99D1-319A643BAAD1

Q35535953-2B6BE405-4DA2-4A45-B78D-2BC90D5A075D

Q35535953-342FB3F2-F470-458A-B4C3-933BD2CB15E3

Q35535953-68093507-B1AC-4E7A-BCF3-E36BB4EFD8D2

Q35535953-68BD5CBE-606A-48CA-AA0B-37CF2FAAD9B9

Q35535953-A2178737-785E-422D-969C-BD52A0FAC727

Q35535953-A63CCF46-45AD-45E5-B2C1-E3CF5D5748AC

Q35535953-B49A58A3-AD84-4B0D-B54D-C31CBDE41804

Q35535953-B6412D40-FCF3-47F3-B435-63B16474C147

Q35535953-D681B392-B2E8-4A3D-B7C5-2EFECC2E7E97

P2860

Q35535953-02888CDC-78F4-4F23-930F-ED17C771942D

Q35535953-09554550-C520-41E9-9303-1EA3F6F88B2B

Q35535953-0E123C78-F596-45AB-ADFA-516E2E9F3C39

Q35535953-1AFC67A8-ECEB-4D17-8D4E-DEEA791F04D5

Q35535953-1F20557C-0703-40DD-AA96-122CFD3B636C

Q35535953-20C44984-4425-47B7-9622-F38F1A873A87

Q35535953-252257DE-7139-4E9D-B11C-49087637AC66

Q35535953-27B8ACF5-468E-4E88-9E51-DCE672DEA367

Q35535953-29D8772D-0329-445A-A123-49A2D26CEC33

Q35535953-2E672680-0A3C-460F-B221-DEDC72843ADF

P304

Q35535953-691E645E-8D28-4247-B75D-F6A1D4657119

P31

Q35535953-770FE744-A093-4310-B5D6-5753A84FA84A

P356

Q35535953-9CD5E5F0-6CF5-4DB2-B294-C767C1DC5B97

P433

Q35535953-A367928B-C536-40B5-A916-ED6B86E84677

P478

Q35535953-0BC7637E-6942-4405-A2E3-9A17E903BC92

P50

Q35535953-4AC7D707-5F78-4E7A-9305-D2E513333E7F

Q35535953-6FC2DB71-4480-4EC2-99C5-31156EE525B8

Q35535953-709A2049-3348-4D45-A21A-6D1EC89AA70B

Q35535953-991A73C6-A87C-4ED5-8737-84EE7D5B2DE6

P577

Q35535953-C4029FF0-98BE-4DBB-85E0-6580F2B74D7E

P5875

Q35535953-0005F31E-4937-4712-B90D-422093854A88

P698

Q35535953-8BB37250-9CDE-497F-8159-0D9592804EB1

P932

Q35535953-ED4140EA-88AD-4E40-A637-39FD50114D25

P356

J.CELREP.2013.12.035

P1433

P1476

Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.

@en

P2093

David S Hong

http://www.w3.org/2001/XMLSchema#string

Gerald S Falchook

http://www.w3.org/2001/XMLSchema#string

J Jack Lee

http://www.w3.org/2001/XMLSchema#string

Jennifer J Wheler

http://www.w3.org/2001/XMLSchema#string

Rajyalakshmi Luthra

http://www.w3.org/2001/XMLSchema#string

Ralph G Zinner

http://www.w3.org/2001/XMLSchema#string

Russell R Broaddus

http://www.w3.org/2001/XMLSchema#string

Sarina A Piha-Paul

http://www.w3.org/2001/XMLSchema#string

Siqing Fu

http://www.w3.org/2001/XMLSchema#string

Stacy L Moulder

http://www.w3.org/2001/XMLSchema#string

P2860

Deregulation of the PI3K and KRAS signaling pathways in human cancer cells determines their response to everolimus

COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers.

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial.

A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer.

Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: a phase 1 dose-escalation trial.

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

P304

377-387

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.CELREP.2013.12.035

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

6

http://www.w3.org/2001/XMLSchema#string

P50

Razelle Kurzrock

Apostolia Maria Tsimberidou

P577

2014-01-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

259807098

http://www.w3.org/2001/XMLSchema#string

P698

24440717

http://www.w3.org/2001/XMLSchema#string

P932

4409143

http://www.w3.org/2001/XMLSchema#string